Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grafalon in Low Immunological Risk Kidney Transplant Recipients
NCT06744400Phase 1Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of antithymocyte globulin rabbit in kidney transplantation (3 arms), sponsored by CHU de Besançon. Primary endpoint: Maximum Tolerated Dose at 4 days. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT06744400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744400.